Carolyn Mcauliffe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022DURHAM, N.C. (BUSINESS WIRE) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused.

United statesRaj kannanHans vitzthumCarolyn mcauliffeAerie pharmaceuticals incDrug administrationRegulatory agencyExchange commissionEuropean medicines agencyAlcon incAerie pharmaceuticalsThird quarter glaucoma franchise net revenuesThird quarterAnnounced agreementTransaction expectedFourth quarter

Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRaj kannanHans vitzthumCarolyn mcauliffeAerie pharmaceuticals incDrug administrationRegulatory agencyExchange commissionEuropean medicines agencyAlcon incAerie pharmaceuticalsQuarter glaucoma franchise net revenuesThird quarterAnnounced agreementTransaction expectedFourth quarter

Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Break Even During 2024DURHAM, N.C.DURHAM, N.C. (BUSINESS WIRE) Aerie Pharm.

United statesRaj kannanHans vitzthumCarolyn mcauliffeAerie pharmaceuticals incDrug administrationRegulatory agencyExchange commissionEuropean medicines agencyAerie pharmaceuticalsSecond quarter glaucoma franchise net revenuesSecond quarterNet cash used expectedCash flow break even duringChief executive officerQuarter financial results

Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Tre

AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye DiseaseCOMET-3 is the second of three studies in the AR-15512 Registrational Phase 3 ProgramDURHAM, N.C. (BUSINESS WIRE) Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company.

United statesNewport beachDavid wirtaHans vitzthumCarolyn mcauliffeMichelle senchynaAerie pharmaceuticals incDrug administrationExchange commissionRegistrational programEye research foundation in newport beachHead of clinical developmentAffairs at aerieAerie pharmaceuticalsDry eyeNew drug application

Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p m ET

Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p m ET
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHans vitzthumCarolyn mcauliffeAerie pharmaceuticals incDrug administrationRegulatory agencyExchange commissionEuropean medicines agencyAerie pharmaceuticalsWall streetDial in timePrivate securities litigation reform actInvestigational new drug applicationsNew drug applicationLifesci advisors